Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events

Published:2022-01-26 Issue:2 Volume:22 Page:203-213
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Kujtan Lara¹^ORCID,Kancha Rama Krishna²,Gustafson Beth³,Douglass Lindsey³,Ward Christopher RH³,Buzard Blake³,Subramanian Janakiraman⁴^ORCID

Affiliation:

1. Department of Medicine, Division of Hematology & Oncology, University of Missouri, Kansas City, USA

2. Molecular Medicine and Therapeutics Laboratory - Osmania University, Hyderabad, India

3. Department of Pharmacy, Saint Luke’s Hospital of Kansas City, Kansas City, USA

4. Department of Medicine, Division of Hematology & Oncology, Saint Luke’s Cancer Institute/University of Missouri Kansas City, Kansas City, USA

Funder

no funding to report

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2029414

Reference63 articles.

1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

3. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

4. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Glycolysis-Related Genes in Lung Squamous Cell Carcinoma;International Journal of Molecular Sciences;2024-01-17

2. Prognostic significance and molecular mechanisms of LPCAT1 in lung squamous cell carcinoma;2024-01-08

3. Establishment of a prognosis prediction model for lung squamous cell carcinoma related to PET/CT: basing on immunogenic cell death-related lncRNA;BMC Pulmonary Medicine;2023-12-15

4. miR-139-5p and miR-451a as a Diagnostic Biomarker in LUSC;Pharmacogenomics and Personalized Medicine;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3